Skip to content

The effect of gluten free diet on gastrointestinal symptoms of individuals with idiopathic dyspepsia who referred to the gastroenterology clinics of Imam Khomeini hospital complex and Dr.Shariati hospital in 2017-2018

The effect of gluten free diet on gastrointestinal symptoms of individuals with idiopathic dyspepsia who referred to the gastroenterology clinics of Imam Khomeini hospital complex and Dr.Shariati hospital in 2017-2018

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017031833112N1
Enrollment
60
Registered
2017-04-22
Start date
2017-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non celiac gluten sensitivity disorder.

Interventions

Intervention 1: Gluten free muffins will given to control group for one week. Intervention 2: Gluten contain muffin (contain about 8gr gluten daily or 160 gr muffin daily) will given to intervention g
Treatment - Other
Gluten free muffins will given to control group for one week.
Gluten contain muffin (contain about 8gr gluten daily or 160 gr muffin daily) will given to intervention group for one week

Sponsors

Researchers
Lead Sponsor
Tehran University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: In this study, patients aged 18 to 55 years old suffering from dyspepsia resistant to treatment and there was no specific cause for them in initial check and celiac disease and allergic to wheat have been ruled out, non-celiac gluten sensitivity (NCGS) are considered. All of the patients underwent 6 weeks of gluten-free diet. Individuals that have no improvement in symptoms, will excluded from our study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Rsolving of intestinal and extraintestinal symptoms. Timepoint: Before the study, at the end of first and third weeks. Method of measurement: Questionnaire of clinical symptoms according to numerical rating scale.

Secondary

MeasureTime frame
Serum anti Anti gliadin IgG level, fecal calprotectin. Timepoint: Before the study, at the end of first and third weeks. Method of measurement: Blood tests (ELISA) and stool tests (ELISA).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Mahdi Fanaeian

Tehran University of Medical Sciences

mfanaeian@razi.tums.ac.ir; mohammadfanaeian@gmail.com+98 21 6119 2101

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026